Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sartorius Stedim Biotech    DIM   FR0013154002

Real-time Quote. Real-time Tradegate - 06/28 10:00:37 pm
69.132 EUR   -1.68%
06/27 SARTORIUS STEDI : Partners with Nova Biomedical
06/01 SARTORIUS STEDI : launches next generation BIOSTAT STR bioreactors
04/19SARTORIUS STEDI : quaterly earnings release
News SummaryMost relevantAll newsSector newsTweets 

SARTORIUS STED BIO : Sartorius Stedim Biotech and c-LEcta sign sales agreement

share with twitter share with LinkedIn share with facebook
share via e-mail
05/03/2012 | 01:05pm CEST
SSB sells and distributes Serratia marcescens nuclease worldwide | Perfect addition to SSB´s purification product portfolio

Goettingen | Leipzig, Germany, May 3, 2012 - Sartorius Stedim Biotech, a leading international pharma and biotech supplier, and the biotechnology specialist c LEcta, announce the signing of a worldwide sales and distribution agreement for c LEcta's proprietary Serratia marcescens nuclease for biopharmaceutical applications. The German company specializes in the development of customized enzymes and production strains for industrial applications. Based on this agreement, customized endonuclease will now be available under the product name "Denarase" through all regular Sartorius Stedim Biotech sales channels.

Endonucleases are used in various biopharmaceutical production processes, such as in recombinant protein production, to remove nucleic acids, reduce viscosity levels and thus optimize process efficiencies. The company c-LEcta has optimized the production process for Serratia marcescens nuclease using a genetically engineered Bacillus strain to increase enzyme activity yields and remove endotoxins. As a result, this new technology enables the highest purity and quality nuclease to be produced.

"This endonuclease provides outstanding advantages from which our customers will benefit directly, such as cost efficiency and high performance," says Dr. Uwe Gottschalk, Vice President of Purification Technologies at Sartorius Stedim Biotech. "The nuclease is a perfect addition to our current purification product portfolio and supports our strategy as a total solution provider for the biopharmaceutical industry."

Dr. Marc Struhalla, Managing Director of c-LEcta comments, "The technology developed by c-LEcta allows us to provide nuclease to our customers in the highest quality. We are convinced that with Sartorius Stedim Biotech, we have found the right sales and distribution partner for the successful worldwide commercialization of our product."

About c-LEcta GmbH

c-LEcta is a German biotechnology company specializing in the development of customized enzymes and production strains for industrial applications. Patented technologies are employed for discovery and optimization of tailor-made enzymes and microbial strains. c-LEcta's know-how in microbiology and strain engineering allows efficient development of production strains for protein and small-molecule products. Proprietary technologies are used for the identification of new enzymes from biodiversity and for effective enzyme engineering.

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
06/27 SARTORIUS STEDIM BIOTECH : Partners with Nova Biomedical
06/01 SARTORIUS STEDIM BIOTECH : launches next generation BIOSTAT STR bioreactors
04/19SARTORIUS STEDIM BIOTECH SA : quaterly earnings release
04/07 SARTORIUS STEDIM BIO : ex-dividend day for annual dividend
04/04 SARTORIUS STEDIM BIOTECH SHS : Resolutions of the Annual Shareholders' Meeting o..
02/21 SARTORIUS STEDIM BIO : Resolutions by the Board of Directors
02/08 SARTORIUS STEDIM BIO : 2016 targets fully achieved; strong outlook for 2017
01/25SARTORIUS STEDIM BIOTECH SA : annual earnings release
01/14 SARTORIUS STEDIM BIOTECH : Opens A New Validation Service Laboratory At Its Shan..
2016 SARTORIUS STEDIM BIOTECH : launches two Single-use Sartocon Loop Assemblies
More news
Sector news : Medical Equipment, Supplies & Distribution - NEC
05/23DJFirms Persuade SEC on Profit Metric -- WSJ
05/22DJCompanies Are Winning the Battle Over Adjusted Earnings
05/16 Earnings drag on European shares, though Vodafone lifts telcos
05/09 French outbound M&A driven to decade high by big deals
05/06DJProfits Jump, Spending Lags -- WSJ
More sector news : Medical Equipment, Supplies & Distribution - NEC
News from SeekingAlpha
04/24 Sartorius Stedim Biotech reports Q1 results
04/03 MKS announces sale of data analytics solutions business
Financials (€)
Sales 2017 1 159 M
EBIT 2017 262 M
Net income 2017 181 M
Debt 2017 100 M
Yield 2017 0,62%
P/E ratio 2017 35,47
P/E ratio 2018 31,55
EV / Sales 2017 5,68x
EV / Sales 2018 5,15x
Capitalization 6 481 M
More Financials
Duration : Period :
Sartorius Stedim Biotech Technical Analysis Chart | DIM | FR0013154002 | 4-Traders
Full-screen chart
Technical analysis trends SARTORIUS STEDIM ...
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus HOLD
Number of Analysts 7
Average target price 67,5 €
Spread / Average Target -4,1%
Consensus details
EPS Revisions
More Estimates Revisions
Joachim Kreuzburg Chairman, CEO, CFO & Head-Human Resources
Volker Niebel Executive Director & Executive VP-Operations
Oscar-Werner Reif Executive Director, EVP-Research & Development
Reinhard Vogt Executive Director, EVP-Marketing & Sales Services
Liliane de Lassus Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MEDTRONIC PLC25.16%121 543
C R BARD INC40.70%22 890
More Results